Leerink Partnrs Issues Negative Estimate for MLTX Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Equities research analysts at Leerink Partnrs lowered their Q3 2025 earnings estimates for shares of MoonLake Immunotherapeutics in a report issued on Tuesday, August 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings per share of ($0.96) for the quarter, down from their prior estimate of ($0.80). The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for MoonLake Immunotherapeutics’ Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($3.45) EPS, FY2026 earnings at ($4.58) EPS, FY2027 earnings at ($5.29) EPS, FY2028 earnings at $1.45 EPS and FY2029 earnings at $7.85 EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.14). During the same period in the previous year, the firm earned ($0.39) EPS.

A number of other research firms have also recently weighed in on MLTX. Wolfe Research raised shares of MoonLake Immunotherapeutics from a “peer perform” rating to an “outperform” rating and set a $61.00 price objective for the company in a research report on Monday, May 19th. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Wedbush reissued an “outperform” rating and issued a $80.00 price target (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. The Goldman Sachs Group raised their price target on shares of MoonLake Immunotherapeutics from $74.00 to $82.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Redburn Atlantic raised shares of MoonLake Immunotherapeutics to a “hold” rating in a research report on Monday, July 28th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $74.43.

MoonLake Immunotherapeutics Stock Performance

NASDAQ:MLTX opened at $52.40 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 21.11 and a current ratio of 16.65. The stock has a market capitalization of $3.35 billion, a P/E ratio of -18.85 and a beta of 1.27. The company has a 50 day moving average price of $48.87 and a 200 day moving average price of $43.16. MoonLake Immunotherapeutics has a fifty-two week low of $31.42 and a fifty-two week high of $58.26.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Deutsche Bank AG lifted its position in shares of MoonLake Immunotherapeutics by 59.8% during the 4th quarter. Deutsche Bank AG now owns 903 shares of the company’s stock worth $49,000 after purchasing an additional 338 shares during the last quarter. US Bancorp DE lifted its position in shares of MoonLake Immunotherapeutics by 114.4% during the 1st quarter. US Bancorp DE now owns 2,208 shares of the company’s stock worth $86,000 after purchasing an additional 1,178 shares during the last quarter. Quarry LP purchased a new stake in shares of MoonLake Immunotherapeutics during the 1st quarter worth $94,000. Advisors Asset Management Inc. lifted its position in shares of MoonLake Immunotherapeutics by 81.7% during the 1st quarter. Advisors Asset Management Inc. now owns 4,009 shares of the company’s stock worth $157,000 after purchasing an additional 1,803 shares during the last quarter. Finally, Birchview Capital LP purchased a new stake in shares of MoonLake Immunotherapeutics during the 4th quarter worth $217,000. Hedge funds and other institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.